A patient considering the wider visual range and optical trade-offs of a full-range IOL

The widest intended range also asks the most of the optics

These lenses aim for the widest unaided range: distance, computer and near. Diffractive full-range models such as PanOptix and Synergy produced large gains in spectacle independence in their pivotal trials. The same trials found more halos or starbursts than with their monofocal controls. That is strong model-level evidence, not permission to paste the same percentages onto every full-range design.

More range is not the same as better vision for every person.

The same person can value the range and notice the night effects

You may read a phone, work at a laptop, and look across a room without changing glasses. Then you drive on a wet, dark road and notice rings around headlights that a monofocal user might not see.

Both experiences can be true in the same successful patient. A good review has to show the useful range and the optical symptoms in the same decision.

Different full-range lenses do not create the same near point or the same visual phenomena. “Trifocal,” “multifocal,” and “full-range” are not precise enough for a decision. The exact model matters.

Who may not want this exchange?

If your top priority is reducing glasses across several distances, you may accept a higher probability of optical phenomena. If your livelihood depends on low-light contrast, the same exchange may be unattractive.

No lens can guarantee zero glasses. “Neuroadaptation” is also not a guarantee that a disturbing symptom will disappear. Persistent or worsening symptoms deserve an eye examination.

Questions for your surgeon

  • Which exact model and near point are you proposing?
  • How were halos measured in its trial?
  • What proportion still used glasses for my most important task?
  • Does my eye have any corneal, macular, optic-nerve, or pupil issue that makes the trade-off less sensible?
  • What is the plan for residual astigmatism, dry eye, or a missed refractive target?
  • Which lower-range alternative would reduce night-vision trade-offs?

Sources: PanOptix FDA SSED; Synergy FDA SSED; ESCRS cataract-surgery guideline.

Next step: Use the questionnaire to state how much glasses independence is worth to you—and what symptom you are not willing to trade for it.

IOL Adviser provides independent education and decision preparation. It does not diagnose, prescribe, or replace an examination by an ophthalmologist. Study averages cannot predict one person’s result.